Pseudoephedrine hydrochloride

201.69

201.09200

206-462-1

6V9V2RYJ8N

759616|106567|33634

C29390

2922199090

32.26000

2.52080

190-191 °C

255ºC at 760mmHg

85.6ºC

Refrigerator (+4°C)

LD50 i.p. in mice: 1.0 mmole/kg (Fairchild, Alles)

61 º (c=5, H2O,2dm tube)

132.1 Ų [M+H-H2O]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

III

6.1(b)

1544

3

22-36/37/38-36/38-39/23/24/25-23/24/25-11

26-36-24/25-45-36/37-16-7

UL5950000

Xn,T,F

P301 + P312 + P330-P305 + P351 + P338

H302-H315-H319

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P272, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 302 companies from 18 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)|Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)

Ephedrine Threo Isomer

Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, hydrochloride (1:1), (.alpha.S)-: ACTIVE

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients